1
|
Rosário JDS, Moreira FH, Rosa LHF, Guerra W, Silva-Caldeira PP. Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome. Molecules 2023; 28:5921. [PMID: 37570891 PMCID: PMC10421188 DOI: 10.3390/molecules28155921] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2023] [Revised: 08/04/2023] [Accepted: 08/05/2023] [Indexed: 08/13/2023] Open
Abstract
Bismuth-based drugs have been used primarily to treat ulcers caused by Helicobacter pylori and other gastrointestinal ailments. Combined with antibiotics, these drugs also possess synergistic activity, making them ideal for multiple therapy regimens and overcoming bacterial resistance. Compounds based on bismuth have a low cost, are safe for human use, and some of them are also effective against tumoral cells, leishmaniasis, fungi, and viruses. However, these compounds have limited bioavailability in physiological environments. As a result, there is a growing interest in developing new bismuth compounds and approaches to overcome this challenge. Considering the beneficial properties of bismuth and the importance of discovering new drugs, this review focused on the last decade's updates involving bismuth compounds, especially those with potent activity and low toxicity, desirable characteristics for developing new drugs. In addition, bismuth-based compounds with dual activity were also highlighted, as well as their modes of action and structure-activity relationship, among other relevant discoveries. In this way, we hope this review provides a fertile ground for rationalizing new bismuth-based drugs.
Collapse
Affiliation(s)
- Jânia dos Santos Rosário
- Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil
| | - Fábio Henrique Moreira
- Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil
| | - Lara Hewilin Fernandes Rosa
- Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil
| | - Wendell Guerra
- Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil
| | | |
Collapse
|
2
|
Ouyang R, Wang S, Feng K, Liu C, Silva DZ, Chen Y, Zhao Y, Liu B, Miao Y, Zhou S. Potent saccharinate-containing palladium(II) complexes for sensitization to cancer therapy. J Inorg Biochem 2023; 244:112205. [PMID: 37028114 DOI: 10.1016/j.jinorgbio.2023.112205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 03/27/2023] [Accepted: 03/29/2023] [Indexed: 04/07/2023]
Abstract
Palladium(II) (PdII) complexes are among the most promising anticancer compounds. Both 2`-benzoylpyridine thiosemicarbazone (BpT) and saccharinate (Sac) are efficient metal chelators with potent anticancer activity. To explore a more effective new anticancer drug, we synthesized a series of Sac and BpT-containing PdII complexes coordinated with thiosemicarbazone (TSC)-derived ligands, and characterized them through nuclear magnetic resonance (NMR), Fourier transformed infrared spectroscopy (FT-IR), elemental analysis, ultraviolet-visible spectroscopy (UV-Vis) and thermogravimetric analysis (TGA). Each target complex was composed of PdII, BpT, and one or two Sac molecules. Both the in vitro and in vivo anti-growth effects of those ligands and the obtained PdII complexes were investigated in the human lung adenocarcinoma cell lines A549 and Spc-A1. The coordination of PdII with the TSC-derivatives and Sac resulted in clearly greater anticancer activity than single ligands. These compounds were demonstrated to be safe for 293 T normal human kidney epithelial cells. The introduction of Sac into the TSC-derived PdII complex significantly enhanced anti-growth effects, and induced apoptosis of human lung cancer cells in vitro and in vivo in a dose dependent manner. Moreover, the PdII complex containing two Sac molecules showed the most promising therapeutic effects, thereby confirming that Sac increases the cancer therapeutic efficacy of PdII complexes and providing a new strategy for exploring anticancer drugs for potential clinical treatment.
Collapse
|
3
|
Bai XG, Zheng Y, Qi J. Advances in thiosemicarbazone metal complexes as anti-lung cancer agents. Front Pharmacol 2022; 13:1018951. [PMID: 36238553 PMCID: PMC9551402 DOI: 10.3389/fphar.2022.1018951] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 09/13/2022] [Indexed: 01/31/2023] Open
Abstract
The great success of cisplatin as a chemotherapeutic agent considerably increased research efforts in inorganic biochemistry to identify more metallic drugs having the potential of treating lung cancer. Metal coordination centres, which exhibit a wide range of coordination numbers and geometries, various oxidised and reduced states and the inherent ligand properties offer pharmaceutical chemists a plethora of drug structures. Owing to the presence of C=N and C=S bonds in a thiosemicarbazone Schiff base, N and S atoms in its hybrid orbital has lone pair of electrons, which can generate metal complexes with different stabilities with most metal elements under certain conditions. Such ligands and complexes play key roles in the treatment of anti-lung cancer. Research regarding metallic anti-lung cancer has advanced considerably, but there remain several challenges. In this review, we discuss the potential of thiosemicarbazone Schiff base complexes as anti-lung cancer drugs, their anti-cancer activities and the most likely action mechanisms involving the recent families of copper, nickel, platinum, ruthenium and other complexes.
Collapse
Affiliation(s)
| | | | - Jinxu Qi
- *Correspondence: Yunyun Zheng, ; Jinxu Qi,
| |
Collapse
|
4
|
Ozturk I, Banti C, Hadjikakou S, Panagiotou N, Tasiopoulos A. Bismuth(III) halide complexes of aromatic thiosemicarbazones: Synthesis, structural characterization and biological evaluation. Polyhedron 2021. [DOI: 10.1016/j.poly.2021.115388] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
5
|
Ahamed M, Akhtar MJ, Khan MAM, Alaizeri ZM, Alhadlaq H. Facile Synthesis of Zn-Doped Bi 2O 3 Nanoparticles and Their Selective Cytotoxicity toward Cancer Cells. ACS OMEGA 2021; 6:17353-17361. [PMID: 34278121 PMCID: PMC8280700 DOI: 10.1021/acsomega.1c01467] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Accepted: 06/03/2021] [Indexed: 05/18/2023]
Abstract
Bismuth (III) oxide nanoparticles (Bi2O3 NPs) have shown great potential for biomedical applications because of their tunable physicochemical properties. In this work, pure and Zn-doped (1 and 3 mol %) Bi2O3 NPs were synthesized by a facile chemical route and their cytotoxicity was examined in cancer cells and normal cells. The X-ray diffraction results show that the tetragonal phase of β-Bi2O3 remains unchanged after Zn-doping. Transmission electron microscopy and scanning electron microscopy images depicted that prepared particles were spherical with smooth surfaces and the homogeneous distribution of Zn in Bi2O3 with high-quality lattice fringes without distortion. Photoluminescence spectra revealed that intensity of Bi2O3 NPs decreases with increasing level of Zn-doping. Biological data showed that Zn-doped Bi2O3 NPs induce higher cytotoxicity to human lung (A549) and liver (HepG2) cancer cells as compared to pure Bi2O3 NPs, and cytotoxic intensity increases with increasing concentration of Zn-doping. Mechanistic data indicated that Zn-doped Bi2O3 NPs induce cytotoxicity in both types of cancer cells through the generation of reactive oxygen species and caspase-3 activation. On the other hand, biocompatibility of Zn-doped Bi2O3 NPs in normal cells (primary rat hepatocytes) was greater than that of pure Bi2O3 NPs and biocompatibility improves with increasing level of Zn-doping. Altogether, this is the first report highlighting the role of Zn-doping in the anticancer activity of Bi2O3 NPs. This study warrants further research on the antitumor activity of Zn-doped Bi2O3 NPs in suitable in vivo models.
Collapse
Affiliation(s)
- Maqusood Ahamed
- King
Abdullah Institute for Nanotechnology, King
Saud University, Riyadh 11451, Saudi Arabia
| | - Mohd Javed Akhtar
- King
Abdullah Institute for Nanotechnology, King
Saud University, Riyadh 11451, Saudi Arabia
| | - M. A. Majeed Khan
- King
Abdullah Institute for Nanotechnology, King
Saud University, Riyadh 11451, Saudi Arabia
| | - ZabnAllah M. Alaizeri
- Department
of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Hisham Alhadlaq
- King
Abdullah Institute for Nanotechnology, King
Saud University, Riyadh 11451, Saudi Arabia
- Department
of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| |
Collapse
|
6
|
Almeida JC, Amim RS, Pessoa C, Lourenço MC, Mendes IC, Lessa JA. Bismuth(III) complexes with pyrazineformamide thiosemicarbazones: Investigation on the antimicrobial and cytotoxic effects. Polyhedron 2020. [DOI: 10.1016/j.poly.2020.114709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
7
|
Piri Z, Moradi–Shoeili Z, Assoud A. Ultrasonic assisted synthesis, crystallographic, spectroscopic studies and biological activity of three new Zn(II), Co(II) and Ni(II) thiosemicarbazone complexes as precursors for nano-metal oxides. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2018.09.054] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
8
|
Cai Y, Sheng Z, Wang J. A Biocompatible Zinc(II)-based Metal-organic Framework for pH Responsive Drug Delivery and Anti-Lung Cancer Activity. Z Anorg Allg Chem 2018. [DOI: 10.1002/zaac.201800248] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Yong Cai
- Department of Radiation Oncology; Shanghai Pulmonary Hospital; Tongji University School of Medicine; Shanghai P. R. China
| | - Zhaoying Sheng
- Department of Radiation Oncology; Shanghai Pulmonary Hospital; Tongji University School of Medicine; Shanghai P. R. China
| | - Jiying Wang
- Department of Oncology; Shanghai Pulmonary Hospital; Tongji University School of Medicine; Shanghai P. R. China
| |
Collapse
|
9
|
Piri Z, Moradi-Shoeili Z, Assoud A. New copper(II) complex with bioactive 2–acetylpyridine-4N-p-chlorophenylthiosemicarbazone ligand: Synthesis, X-ray structure, and evaluation of antioxidant and antibacterial activity. INORG CHEM COMMUN 2017. [DOI: 10.1016/j.inoche.2017.08.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
10
|
Jia P, Ouyang R, Cao P, Tong X, Zhou X, Lei T, Zhao Y, Guo N, Chang H, Miao Y, Zhou S. Review: recent advances and future development of metal complexes as anticancer agents. J COORD CHEM 2017. [DOI: 10.1080/00958972.2017.1349313] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Pengpeng Jia
- University of Shanghai for Science and Technology, Shanghai, China
| | - Ruizhuo Ouyang
- University of Shanghai for Science and Technology, Shanghai, China
| | - Penghui Cao
- University of Shanghai for Science and Technology, Shanghai, China
| | - Xiao Tong
- Cancer Institute, Tongji University School of Medicine, Shanghai, China
| | - Xia Zhou
- University of Shanghai for Science and Technology, Shanghai, China
| | - Tian Lei
- University of Shanghai for Science and Technology, Shanghai, China
| | - Yuefeng Zhao
- University of Shanghai for Science and Technology, Shanghai, China
| | - Ning Guo
- University of Shanghai for Science and Technology, Shanghai, China
| | - Haizhou Chang
- University of Shanghai for Science and Technology, Shanghai, China
| | - Yuqing Miao
- University of Shanghai for Science and Technology, Shanghai, China
| | - Shuang Zhou
- University of Shanghai for Science and Technology, Shanghai, China
| |
Collapse
|